[Uniqueness of the mucosal immune system for the development of prospective mucosal vaccine].
The mucosal immune system acts as the first line of defense against microbial infection through a dynamic immune network based on innate and acquired mucosal immunity. To prevent infectious diseases, it is pivotal to develop effective mucosal vaccines that can induce both mucosal and systemic immune responses, especially secretory IgA (S-IgA) and plasma IgG, against pathogens. Recent advances in medical and biomolecular engineering technology and progress in cellular and molecular immunology and infectious diseases have made it possible to develop versatile mucosal vaccine systems. In particular, mucosal vaccines have become more attractive due to recent development and adaptation of new types of drug delivery systems not only for the protection of antigens from the harsh conditions of the mucosal environment but also for effective antigen delivery to mucosa-associated lymphoid tissues such as Peyer's patches and nasopharynx-associated lymphoid tissue, the initiation site for the induction of the antigen-specific immune response. In this review, we shed light on the dynamics of the mucosal immune system and recent advances toward the development of prospective mucosal antigen delivery systems for vaccines.
Kunisawa
Jun
J
Division of Mucosal Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan. kunisawa@ims.u-tokyo.ac.jp
Gohda
Masashi
M
Kiyono
Hiroshi
H
D000941:Antigens / Q000276:immunology; D003140:Communicable Disease Control; D016503:Drug Delivery Systems; D006801:Humans; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D008221:Lymphoid Tissue / Q000276:immunology; D009092:Mucous Membrane / Q000276:immunology*; D009305:Nasopharynx / Q000276:immunology; D010581:Peyer's Patches / Q000276:immunology; D014612:Vaccines
D000941:Antigens; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D014612:Vaccines